A Phase 2 interventional study of cAd3-Sudan Vaccine and Placebo in Ebola Sudan Virus Disease, sponsored by Albert B. Sabin Vaccine Institute. Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-10.
Sponsored by Albert B. Sabin Vaccine Institute · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
This is a multi-center, double-blinded, placebo-controlled, Phase 2 study to evaluate safety, tolerability, and immunogenicity of a single dose of cAd3-Sudan Vaccine in healthy adults up to 70 years of age. The study will enroll 200 eligible participants randomized 4:1 to receive the cAd3-Sudan Vaccine at 1.0 × 10\^11 PU dose or placebo (0.9% sodium chloride (NaCl) solution) at Day 1, intramuscularly in deltoid muscle. Participants will be screened for eligibility up to 28 days before enrollment. Safety data will be periodically reviewed by an independent DSMB. Safety and immunogenicity will be assessed at Days 1, 8, 15, 29, 85, 169, and will conclude at the end of study visit on Day 366. PBMCs will be collected from a subset of 40 subjects on days 1, 15, 29, 169 and 366 to access cellular immunity.
Albert B. Sabin Vaccine Institute is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has a (BMI) >17 and ≤ 37 at screening.
Female participant specific criteria:
Use of oral, implantable, transdermal or injectable for 21 days prior to vaccination and for at least 24 weeks after vaccination, UNLESS the participant fulfills one of the following criteria:
Male participants must agree:
Exclusion Criteria:
History of or active status of any of the following conditions:
Hematologic History:
Receipt of any of the following substances:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of cAd3-Sudan Vaccine (1x10\^11 PU) administered intramuscularly (IM) with needle and syringe in a volume of 0.83 mL.
Biological: cAd3-Sudan Vaccine
Single dose of Placebo (0.9% NaCl solution for injection) administered intramuscularly (IM) with needle and syringe in a volume of 0.83 mL.
Biological: Placebo
The recombinant chimpanzee adenovirus Type 3-vectored Sudan Ebolavirus vaccine, (cAd3-Sudan) is composed of a cAd3 vector that expresses wild type glycoprotein (WT GP) from the Sudan Gulu ebolavirus strain.
0.9% NaCl solution for injection.
To determine the percentage of vaccinated participants who develop SAEs, AEs, and AESI from cAd3-Sudan Vaccine and placebo
Count and percentage of vaccinated participants who develop: - serious adverse events (SAEs), - solicited adverse events (AEs), - unsolicited AEs, - adverse event of special interest (AESI), - medically attended adverse events (MAAE), - AE at each intensity level. Estimand 1a (Primary): Count and percentage of vaccinated participants who would develop SAEs, solicited AEs, unsolicited AEs, AESI, MAAE, and AE at each intensity level will be evaluated with each treatment group. A treatment policy strategy is used for assessing safety irrespective of a current (or prior) infection at time of the vaccination. Infections and death (if the participant meet the AE and time window criteria) are included in the endpoint (composite strategy).
Time frame: 1 Year
To determine the geometric mean concentration (GMC) of the antibody response (IgG) to cAd3-Sudan Vaccine at Day 29 post-vaccination.
Secondary Endpoint: To evaluate the humoral immunogenicity of anti-SUDV-GP binding IgG antibodies at Day 29 post-vaccination. Estimand 2a: Geometric mean concentration (GMC) of the vaccine group will be compared to placebo at Day 29 post-vaccination. The hypothetical strategy is used to estimate antibody levels without subsequent Sudan Ebolavirus (SUDV) infection or influence from immune-modifying drugs or non-study vaccines. The principal stratum strategy excludes those with active or prior SUDV infection at the time of the vaccination.
Time frame: 29 Days
To determine geometric mean increase (GMI) of anti-SUDV-GP binding IgG antibodies at Day 29 post-vaccination
Secondary Endpoint: To evaluate the humoral immunogenicity of anti-SUDV-GP binding IgG antibodies at Day 29 post-vaccination. Estimand 2b: Geometric mean increase (GMI) of anti-SUDV-GP binding IgG antibodies against SUDV-GP on Day 29. The hypothetical strategy is used to estimate antibody levels without subsequent Sudan Ebolavirus (SUDV) infection or influence from immune-modifying drugs or non-study vaccines. The principal stratum strategy excludes those with active or prior SUDV infection at the time of the vaccination.
Time frame: 29 Days
To determine the geometric mean of the ND50 (GMND50) of anti-SUDV-GP neutralizing antibodies on Day 29 post-vaccination.
Secondary Endpoint: To evaluate the humoral immunogenicity of anti-SUDV-GP binding IgG antibodies at Day 29 post-vaccination. Estimand 2c: The geometric mean of the ND50 (GMND50) of anti-SUDV-GP neutralizing antibodies on Day 29. The hypothetical strategy is used to estimate antibody levels without subsequent Sudan Ebolavirus (SUDV) infection or influence from immune-modifying drugs or non-study vaccines. The principal stratum strategy excludes those with active or prior SUDV infection at the time of the vaccination.
Time frame: 29 Days
To determine the geometric mean increase of the ND50 (GMIND50) of anti-SUDV-GP neutralizing antibodies at Day 29 post-vaccination.
Secondary Endpoint: To evaluate the humoral immunogenicity of anti-SUDV-GP binding IgG antibodies at Day 29 post-vaccination. Estimand 2d: The geometric mean increase of the ND50 (GMIND50) of anti-SUDV-GP neutralizing antibodies on Day 29. The hypothetical strategy is used to estimate antibody levels without subsequent Sudan Ebolavirus (SUDV) infection or influence from immune-modifying drugs or non-study vaccines. The principal stratum strategy excludes those with active or prior SUDV infection at the time of the vaccination.
Time frame: 29 Days
To determine the percentage of participants (and 95%CI) with seroconversion at Day 29 post-vaccination.
Secondary Endpoint: Humoral immunogenicity of anti-SUDV-GP binding IgG antibodies at Day 29 post-vaccination. Estimand 2e: Percentage of participants (and 95%CI) with seroconversion at Day 29. The hypothetical strategy is used to estimate antibody levels without subsequent Sudan Ebolavirus (SUDV) infection or influence from immune-modifying drugs or non-study vaccines. The principal stratum strategy excludes those with active or prior SUDV infection at the time of the vaccination.
Time frame: 29 Days
To determine the geometric mean concentration (GMC) of anti-SUDV-GP binding IgG antibodies on Day 1, Day 8, Day 15, Day 85, Day 169, and Day 366.
Secondary Endpoint: To evaluate the humoral immunogenicity of anti-SUDV-GP binding IgG antibodies across additional timepoints. Estimand 3a: GMCs of anti-SUDV-GP binding IgG antibodies on Day 1, Day 8, Day 15, Day 85, Day 169, and Day 366. The hypothetical strategy is used to estimate antibody levels without subsequent Sudan Ebolavirus (SUDV) infection or influence from immune-modifying drugs or non-study vaccines.
Time frame: 1 Year
To determine the geometric mean increase (GMI) of anti-SUDV-GP binding IgG antibodies against SUDV-GP at optional selected timepoints (Day 8, Day 15, Day 85, Day 169, and Day 366).
Secondary Endpoint: To evaluate the humoral immunogenicity of anti-SUDV-GP binding IgG antibodies across additional timepoints. Estimand 3b: GMI of anti-SUDV-GP binding IgG antibodies against SUDV-GP at optional selected timepoints (Day 8, Day 15, Day 85, Day 169, and Day 366). The hypothetical strategy is used to estimate antibody levels without subsequent Sudan Ebolavirus (SUDV) infection or influence from immune-modifying drugs or non-study vaccines.
Time frame: 1 Year
To determine geometric mean increase of the ND50 (GMIND50) of anti-SUDV-GP neutralizing antibodies on Day 1, Day 8, Day 15, Day 85, Day 169, and Day 366.
Secondary Endpoint: To evaluate the humoral immunogenicity of anti-SUDV-GP binding IgG antibodies across additional timepoints. Estimand 3c: GMIND50 of anti-SUDV-GP neutralizing antibodies on Day 1, Day 8, Day 15, Day 85, Day 169, and Day 366. The hypothetical strategy is used to estimate antibody levels without subsequent Sudan Ebolavirus (SUDV) infection or influence from immune-modifying drugs or non-study vaccines.
Time frame: 1 Year
To determine geometric mean increase of ND50 (GMIND50) of anti-SUDV-GP neutralizing antibodies at optionally selected timepoints (Day 8, Day 15, Day 85, Day 169, and Day 366)
Secondary Endpoint: To evaluate the humoral immunogenicity of anti-SUDV-GP binding IgG antibodies across additional timepoints. Estimand 3d: GMIND50 of anti-SUDV-GP neutralizing antibodies at optionally selected timepoints (Day 8, Day 15, Day 85, Day 169, and Day 366). The hypothetical strategy is used to estimate antibody levels without subsequent Sudan Ebolavirus (SUDV) infection or influence from immune-modifying drugs or non-study vaccines.
Time frame: 1 Year
To determine the percentage of participants (and 95%CI) with seroconversion at Day 8, Day 15, Day 85, Day 169, and Day 366.
Secondary Endpoint: To evaluate the humoral immunogenicity of anti-SUDV-GP binding IgG antibodies across additional timepoints. Estimand 3e: Percentage of Participants (and 95%CI) with seroconversion at Day 8, Day 15, Day 85, Day 169, and Day 366. The hypothetical strategy is used to estimate antibody levels without subsequent Sudan Ebolavirus (SUDV) infection or influence from immune-modifying drugs or non-study vaccines.
Time frame: 1 Year
To determine cell-mediated immune response (IFN-γ secreting T cells) to cAd3-Sudan Vaccine at Day 1, Day 15, Day 29, Day 169, and Day 366 in a subset of 40 Participants
Exploratory Objective: Further exploratory immunology to detect cAd3-Sudan Vaccine-related immune responses. Estimand 4a: Frequency of IFN-γ secreting T cells by ELISpot. The hypothetical strategy is used to estimate cytokine levels without subsequent Sudan Ebolavirus (SUDV) infection or influence from immune-modifying drugs or non-study vaccines.
Time frame: 1 year
To determine cell-mediated immune response (CD4+ T-cells and/or CD8+ T-cells producing IFN-γ and/or IL-2 and/or TNF-α) to cAd3-Sudan Vaccine at Day 1, Day 15, Day 29, Day 169, and Day 366 in a subset of 40 Participants
Exploratory Objective: Further exploratory immunology to detect cAd3-Sudan Vaccine-related immune responses. Estimand 4b: Percentage of CD4+ T-cells and/or CD8+ T-cells that produce IFN-γ and/or IL-2 and/or TNF-α. The hypothetical strategy is used to estimate cytokine levels without subsequent Sudan Ebolavirus (SUDV) infection or influence from immune-modifying drugs or non-study vaccines.
Time frame: 1 Year
To determine the geometric mean concentration (GMC) of anti-SUDV-GP binding IgM antibodies at Day 1, Day 8, Day 15, and Day 29.
Exploratory Objective: Further exploratory immunology to detect cAd3-Sudan Vaccine-related immune responses. Estimand 4c: The GMC of anti-Sudan-GP binding IgM antibodies at Day 1, Day 8, Day 15, and Day 29. The hypothetical strategy is used to estimate antibodies levels without subsequent Sudan Ebolavirus (SUDV) infection or influence from immune-modifying drugs or non-study vaccines.
Time frame: 29 Days
To determine systems serology (multiple assays in high throughout screen) D1 and D29
Exploratory Objective: Further exploratory immunology to detect cAd3-Sudan Vaccine-related immune responses. Estimand 4d: Systems serology (multiple assays in high throughout screen) D1 and D29. The hypothetical strategy is used to estimate antibodies levels without subsequent Sudan Ebolavirus (SUDV) infection or influence from immune-modifying drugs or non-study vaccines.
Time frame: 29 Days
Plan to share: Yes — The clinic trial results will be published in a peer-reviewed journal, which will include, as feasible, the study protocol. A summary of the study results will be included within the trial registration records in ClinicalTrials.gov.
Supporting information: Clinical study report
Time frame: The sponsor will also publish results in a manuscript in a peer reviewed journal, which requires a published study protocol. The sponsor expects this will be completed by late 2027.
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Feb 2027, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Albert B. Sabin Vaccine Institute